The MarketVue®: Tardive Dyskinesia (TD) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
- Disease overview: Review the disease pathophysiology and potential druggable targets
- Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
- Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
- Unmet needs: Identify opportunities to address treatment or disease management gaps
- Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
- Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Tardive Dyskinesia (TD) report is supported by 7 qualitative interviews with key opinion leaders, a quantitative survey with 24 U.S. physicians and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom).
Key companies mentioned:
- Teva Pharmaceuticals
- Neurocrine Biosciences
- Luye Pharma Group
Key drugs mentioned:
- Deutetrabenazine (Austedo)
- Valbenazine (Ingrezza)
- Clonazepam (Klonopin, Rivotril)
- Botulinum toxin injections (Botox)
- Reserpine (Serpasil)
- Tetrabenazine (Nitoman, Xenazine)
- LY03015
- Acamprosate calcium
- Sarizotan
Key takeaways from the report:
Tardive dyskinesia (TD) is a medication-induced neurological disorder which disrupts patients’ quality of life with complications that include:
- Tapping or shaking of the fingers and hands
- Puckering and frowning of the mouth and darting tongue
- Rapid or constant blinking
- Movements of the trunk
According to TD experts interviewed, most TD patients are well-controlled with one of the two FDA-approved VMAT2 inhibitors. Austedo and Ingrezza are viewed as comparable options due to their similar efficacy, side effect profiles, and now, dosing convenience with the introduction of Austedo extended-release tablets. Consequently, individual physician preference is driven most often by prior experience and familiarity with a drug.
Psychiatrist, U.S.: 'I mean it’s amazing to see what they [VMAT2 inhibitors] can do to people who had suffered for many years and whose lives had been very much destroyed by [TD].'
The report indicates that given the success of Austedo and Ingrezza, clinicians do not perceive a high unmet need for novel TD treatments, which is also reflected in the sparse TD pipeline. However, experts say they have observed a rise in prescriptions for dopamine receptor blocking agents beyond use in schizophrenia, expanding to wider use in other conditions:
- Major depressive disorder
- Bipolar disorder
- Gastroparesis
- Behavior conditions (e.g., autism)
This suggests a potential surge in TD cases in the future which underscores the growing demand for efficacious medications that avoid directly inhibiting the dopamine pathway, working to effectively prevent TD.
Psychiatrist, U.S.: 'The future is not treating TD. I think the future is not inducing it… we may solve the problem by just not having drugs that cause the problem to begin with.
Table of Contents
1. DISEASE OVERVIEW- A medication-induced neurological disorder causing involuntary, repetitive body movements
- Figure 1.1 Problematic symptoms of TD
- Table 1.1 Risk factors for TD
- The role of dopamine in the disease mechanism of TD
- Figure 1.2 The role of dopamine in the hypothesized pathogenesis and current treatment of TD
- Disease Definition
- Figure 2.1. Diagnosed prevalent cases of TD by region
- Table 2.1 Diagnosed prevalence cases of TD in the US and EU5
- Upper-end estimates of the prevalence of TD in the US
- Table 2.2 Upper-end estimates of the diagnosed prevalence cases of TD in the US using 2023 MDPS estimates of schizophrenia prevalence
- Table 2.3. TD diagnosed prevalence estimates in the U.S. using antipsychotic prescription volume
- Figure 2.1. KOL commentary on increasingly widespread antipsychotic use
- Diagnosis Overview
- Figure 3.1. Diagnostic pathway for TD patients
- Treatment flow for TD involves balance between DRAs and VMAT2 inhibitors
- Table 3.1. TD treatment goals
- Figure 3.2. Treatment algorithm for management of TD
- Severity and patient response to VMAT2 inhibitors
- Figure 3.3. KOL estimate of diagnosed TD patients receiving drug treatment1
- Comparison of FDA approved treatments for TD
- Table 3.2. Comparison of FDA approved TD treatments
- Clinical trial primary endpoint success drove FDA approval for TD therapies
- Figure 3.4. Austedo and Ingrezza pivotal trial primary outcome results
- Figure 3.5. Austedo and Ingrezza pivotal trial secondary outcome results
- Physician perspectives on Austedo and Ingrezza
- Table 3.3. KOL commentary on Austedo and Ingrezza
- Table 3.4. Physician perspective on the efficacy of Austedo and Ingrezza
- Figure 3.6. KOL estimates of current VMAT2 treatment share (n=24)
- Key treatment dynamics that will shape disease management and drug use in TD
- Table 3.5. Must-know TD market dynamics
- No significant changes are anticipated to disrupt the TD market in the foreseeable future
- Figure 3.7. Important dynamics of TD market evolution
- Overview
- Figure 4.1. Top unmet needs in TD
- Figure 4.2 Physician-reported high unmet need patient types
- Physician perspectives on unmet needs in TD
- Overview
- Table 5.1 Summary of phase 1 trial of LY03015
- Physician perspectives on diagnostic and therapeutic developments in TD
- Overview
- Table 6.1. Comparison of treatment pricing, U.S.
- Table 6.2. Typical U.S. commercial payer coverage
- Despite support programs, existing TD drugs still have barriers to access
- Figure 6.1. Resources offered by Teva and Neurocrine to help facilitate patient access
- Figure 6.2. KOL reported barriers to patient access1
- Primary market research approach
- Epidemiology methodology
- Epidemiology methodology: schizophrenia prevalence model
- Epidemiology methodology: antipsychotic prescription volume model
- Table 7.1 Epidemiology references
Samples
LOADING...
Companies Mentioned
- Teva Pharmaceuticals
- Neurocrine Biosciences
- Luye Pharma Group
